{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:41:15Z","timestamp":1793396475493,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Medical Research Council (NMRC) Collaborative Centre Grant scheme","award":["NMRC\/CG21APRC006"],"award-info":[{"award-number":["NMRC\/CG21APRC006"]}]},{"name":"CArdiovascular DiseasE National Collaborative Enterprise","award":["MOH-001277"],"award-info":[{"award-number":["MOH-001277"]}]},{"name":"National Medical Research Council (NMRC) Centre Grant scheme","award":["NMRC CG21APR1006"],"award-info":[{"award-number":["NMRC CG21APR1006"]}]},{"name":"Singapore Translational Research Investigator Award","award":["STaR21jun-0003"],"award-info":[{"award-number":["STaR21jun-0003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe prescription patterns, dosing and persistence of guideline-directed medical therapy (GDMT) among patients with heart failure with reduced ejection fraction in Singapore, and to identify factors associated with the use of quadruple therapy (ACE inhibitor (ACEi)\/angiotensin II receptor blocker (ARB)\/angiotensin receptor-neprilysin inhibitor (ARNI), \u03b2-blocker, mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Secondary and tertiary care settings across seven public hospitals in Singapore.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>3999 adults hospitalised from 2020 to 2022 with a first heart failure-related admission and left ventricular ejection fraction \u226440%. Patients with absolute contraindications to specific GDMT classes were excluded from eligibility calculations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Primary outcomes were the proportions of eligible patients prescribed each GDMT class and quadruple therapy at discharge. Secondary outcomes were 6-month prescription patterns, dose attainment and predictors of quadruple therapy use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among eligible patients, 80%\u201399% met criteria for each GDMT drug class, yet only 29% received quadruple therapy at discharge in 2022. Prescription rates for ACEi\/ARB\/ARNI (67%), beta-blockers (89%), MRAs (40%), and SGLT2 inhibitors (46%) remained suboptimal despite high eligibility. At discharge, over 90% of patients on ACEi\/ARB\/ARNI and beta-blockers received \u226450% of target doses. By 6\u2009months, prescription rates declined by 16% for ACEi\/ARB\/ARNI, 26% for beta-blockers and 7% for MRAs, while SGLT2 inhibitor use increased. Older age (OR 0.97, 95%\u2009CI 0.96 to 0.98)\u2009and chronic kidney disease stage 3a\u20134 (OR 0.65 to 0.04) were associated with lower odds of receiving quadruple therapy, while significant institutional variation was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite high eligibility, uptake and optimisation of GDMT remain poor in Singapore, with substantial treatment gaps driven by underprescription, inadequate dosing and discontinuation. Interventions targeting clinician awareness, postdischarge support and institutional practice variation may improve adherence to guideline-recommended therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107127","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:55:33Z","timestamp":1773327333000},"page":"e107127","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03760705","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5606-2046","authenticated-orcid":false,"given":"Sameera","family":"Senanayake","sequence":"first","affiliation":[{"name":"Health Services Research & Population Health, Duke-NUS Medical School, Singapore"},{"name":"National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore"},{"name":"Australian Centre for Health Services Innovation (AusHSI), Queensland University of Technology, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audry Shan Yin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Heart Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-3267","authenticated-orcid":false,"given":"Nicholas","family":"Graves","sequence":"additional","affiliation":[{"name":"Health Services Research & Population Health, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoo Pyae Sone","family":"Win","sequence":"additional","affiliation":[{"name":"Health Services Research & Population Health, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Lee","sequence":"additional","affiliation":[{"name":"National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee How","family":"Lau","sequence":"additional","affiliation":[{"name":"National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Hausenloy","sequence":"additional","affiliation":[{"name":"National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore"},{"name":"Cardiovascular & Metabolic Disorders Program, Duke-NUS Medical School, Singapore"},{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"The Hatter Cardiovascular Institute, University College London, London, UK"},{"name":"Cardiovascular Disease National Collaborative Enterprise, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khung-Keong","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Heart Centre Singapore, Singapore"},{"name":"Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Yan-Yee","family":"Chan","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Cardiovascular Disease National Collaborative Enterprise, Singapore"},{"name":"Department of Cardiology, National University Heart Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Ching Chiew","family":"Wong","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Department of Cardiology, National University Heart Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seet Yoong","family":"Loh","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kheng Leng David","family":"Sim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Heart Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weien","family":"Chow","sequence":"additional","affiliation":[{"name":"Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Bryan","family":"Tan","sequence":"additional","affiliation":[{"name":"Ministry of Health Singapore, Singapore"},{"name":"Saw Swee Hock School of Public Health, National University Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeewa","family":"Kularatna","sequence":"additional","affiliation":[{"name":"Health Services Research & Population Health, Duke-NUS Medical School, Singapore"},{"name":"National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore"},{"name":"Australian Centre for Health Services Innovation (AusHSI), Queensland University of Technology, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026062609363387000_16.3.e107127.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168780","article-title":"A Need to Preserve Ejection Fraction during Heart Failure","volume":"25","author":"Akinterinwa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026062609363387000_16.3.e107127.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2015.12.002"},{"key":"2026062609363387000_16.3.e107127.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy005"},{"key":"2026062609363387000_16.3.e107127.4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2021.02.035","article-title":"Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study","volume":"330","author":"Hsiao","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026062609363387000_16.3.e107127.5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2459\/JCM.0000000000001426","article-title":"Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium\u2013glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis","volume":"24","author":"Huang","year":"2023","journal-title":"J Cardiovasc Med"},{"key":"2026062609363387000_16.3.e107127.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.01.017"},{"key":"2026062609363387000_16.3.e107127.7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamacardio.2024.3023","article-title":"Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure","volume":"9","author":"Tang","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026062609363387000_16.3.e107127.8","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2026062609363387000_16.3.e107127.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"2026062609363387000_16.3.e107127.10","first-page":"1365","article-title":"Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC: Heart Failure"},{"key":"2026062609363387000_16.3.e107127.11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1253\/circrep.CR-19-0106","article-title":"Building a Longitudinal National Integrated Cardiovascular Database \u2015 Lessons Learnt From SingCLOUD","volume":"2","author":"Yeo","year":"2020","journal-title":"Circ Rep"},{"key":"2026062609363387000_16.3.e107127.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2026062609363387000_16.3.e107127.13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3102\/1076998616687084","article-title":"Multiple Imputation Under Violated Distributional Assumptions: A Systematic Evaluation of the Assumed Robustness of Predictive Mean Matching","volume":"42","author":"Kleinke","year":"2017","journal-title":"J Educ Behav Stat"},{"key":"2026062609363387000_16.3.e107127.14","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/26.1.224"},{"key":"2026062609363387000_16.3.e107127.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-019-01588-7"},{"key":"2026062609363387000_16.3.e107127.16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029071","article-title":"Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge","volume":"12","author":"D\u2019Amario","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026062609363387000_16.3.e107127.17","article-title":"Trends in Medical and Device Therapies Following Incident Heart Failure in Denmark during 1996-2019: A Nationwide Register-Based Follow-Up Study","volume":"10","author":"Ettrup-Christensen","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026062609363387000_16.3.e107127.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2022-6-4","article-title":"Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction","volume":"12","author":"Ospina Gonz\u00e1lez","year":"2023","journal-title":"DIC"},{"key":"2026062609363387000_16.3.e107127.19","first-page":"1","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"Heart Fail"},{"key":"2026062609363387000_16.3.e107127.20","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/jep.13885","article-title":"Clinician challenges to evidence-based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation","volume":"29","author":"Trinkley","year":"2023","journal-title":"J Eval Clin Pract"},{"key":"2026062609363387000_16.3.e107127.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.09.059"},{"key":"2026062609363387000_16.3.e107127.22","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314158"},{"key":"2026062609363387000_16.3.e107127.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"2026062609363387000_16.3.e107127.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2026062609363387000_16.3.e107127.25","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2021.33","article-title":"Management of Heart Failure in Patients with Chronic Kidney Disease","volume":"17","author":"Ryan","year":"2022","journal-title":"Eur Cardiol"},{"key":"2026062609363387000_16.3.e107127.26","unstructured":"Agency for Care Effectiveness (ACE) . Sacubitril\/valsartan for treating chronic heart failure with reduced ejection fraction: Ministry of Health, Singapore. 2022. Available: https:\/\/www.ace-hta.gov.sg\/docs\/default-source\/drug-guidances\/sacubitril-valsartan-for-treating-chf-with-reduced-ejection-fraction-%284-jan-2022%29.pdf"},{"key":"2026062609363387000_16.3.e107127.27","unstructured":"Agency for Care Effectiveness (ACE) . SGLT2 inhibitors for treating heart failure and chronic kidney disease: Ministry of Health, Singapore. 2024. Available: https:\/\/www.ace-hta.gov.sg\/docs\/default-source\/drug-guidances\/sglt2-inhibitors-for-chronic-heart-failure-and-chronic-kidney-disease-%28updated-2-jan-2024%29.pdf?sfvrsn=e9aefb33_6"},{"key":"2026062609363387000_16.3.e107127.28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036998","article-title":"Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF","volume":"13","author":"Shoji","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:41:37Z","timestamp":1782492097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-107127"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107127","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}